- Supernus Pharmaceuticals | Innovating CNS Treatments
Supernus, a biopharmaceutical company, develops CNS disease treatments Transforming patient care with cutting-edge therapies and strategic partnerships
- Supernus Pharmaceuticals, Inc. (SUPN) Stock Price, News . . .
Find the latest Supernus Pharmaceuticals, Inc (SUPN) stock quote, history, news and other vital information to help you with your stock trading and investing
- Supernus Pharmaceuticals to Acquire Sage Therapeutics,
ROCKVILLE, Md and CAMBRIDGE, Mass , June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc (Nasdaq: SUPN) and Sage Therapeutics, Inc (Nasdaq: SAGE), today announced a definitive
- Come join our talented, hardworking team at Supernus. Our . . .
Supernus Pharmaceuticals, Inc attracts, inspires and rewards exceptionally talented and motivated people We offer opportunities for personal growth and success by supporting excellence and encouraging continuous improvement
- Supernus Pharmaceuticals (SUPN) Stock Price Overview
A detailed overview of Supernus Pharmaceuticals, Inc (SUPN) stock, including real-time price, chart, key statistics, news, and more
- Supernus Medical Affairs – Advancing CNS Science for . . .
Explore educational resources and detailed information about Supernus Medical Affairs' therapeutic areas, innovative treatments, and product pipeline in psychiatry and neurology
- Supernus infusion device is cleared by FDA for Parkinsons . . .
More than four years after it faced its first regulatory setback in Parkinson's disease, Supernus Pharmaceuticals has at last won FDA approval for its subcutaneous apomorphine infusion device, which will launch next quarter
|